FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
Metastatic basal cell carcinoma to the bone: a case of bone metastasis in uncommon sites
1143PDF: 540Supplementary Table: 256HTML: 26 -
10 | LEBRIKIZUMAB PROVIDES CLINICALLY MEANINGFUL RESPONSE IN FACE AND HANDS IN ADULTS AND ADOLESCENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: ADHOPE 1 STUDY L. Stingeni1, C. Vestergaard2, J. Seneschal3|4, S. Weidinger5, A. Wollenberg6|7|8, A. Irvine9, H. Agell10, J. Valls Bancells10, V. Sapena10, D. Thaçi7 | 1Dermatology Section, Department of Medicine and Surgery, University of Perugia, Italy; 2Department of Dermatology and Venerology, Aarhus University Hospital, Aarhus, Denmark; 3Department of Dermatology, University of Bordeaux, Bordeaux, France; 4Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, Hospital Saint-André, Bordeaux, France; 5Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany; 6University Medical Center of Augsburg, Augsburg, Germany; 7Institute and Comprehensive Center for Inflammatory Medicine at the University of Lübeck, Lübeck, Germany; 8Department of Dermatology and Allergology, LMU Hospital, Munich, Germany; 9Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland; 10Almirall S.A., Barcelona, Spain
231PDF: 161 -
Apalutamide-induced ichthyosiform eruption
824PDF: 521HTML: 59 -
-
Churg-Strauss syndrome and hemorragic vasculitis
1632PDF: 816HTML: 1085 -
Post-inflammatory hyperpigmentation after carbon dioxide laser: review of prevention and risk factors
6548PDF: 980APPENDIX 1: 171HTML: 231 -
-
26 | CONCOMITANT THERAPY WITH IXEKIZUMAB PLUS TIRZEPATIDE IN ADULTS WITH PSORIATIC ARTHRITIS AND OVERWEIGHT OR OBESITY DEMONSTRATED SUPERIOR DISEASE CONTROL COMPARED TO IXEKIZUMAB ALONE: RESULTS FROM THE PH3B TOGETHER-PSA TRIAL E. Filippi1, J. F. Merola2, P. Mease3, A. Kivitz4, N. Sattar5, L. C. Coates6, C. E. Kartman7, P. Fischer7, L. Sun7, A. Cardoso7, M. C. Genovese7, A. Ogdie8 | 1Eli Lilly Italia S.p.A, Florence, Italy; 2Department of Dermatology and Department of Medicine, Division of Rheumatology, UT Southwestern Medical Center and O’Donnell School of Public Health, Dallas, TX, USA; 3Providence Swedish Medical Center, Seattle, WA, USA; 4Altoona Center for Clinical Research, Duncansville, PA, USA; 5School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK; 6Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; 7Eli Lilly and Company, Indianapolis, IN, USA; 8Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
147PDF: 60 -
30 | Sonidegib for nevoid basal cell carcinoma (Gorlin) syndrome and EADO stage IIb sporadic basal cell carcinomas: a phase II study (SIBLINGS trial) Sara Farinatti1|2, Giuseppe Agenziano3, Emi Dika4|5, Emanuela Passoni6, Ketty Peris7, Pietro Quaglino8, Paola Queirolo9, Massimiliano Scalvenzi10, Iris Zalaudek11, Luigi Lorini11, Cristina Gurizzan1, Monica Variolo1|2, Paolo Bossi*1|2, Carlo Resteghini*1|2 | 1Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milano; 2Department of Biomedical Sciences, Humanitas University, Rozzano MI; 3Unit of Dermatology, Luigi Vanvitelli University of Campania, Naples; 4Oncologic Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna; 5Department of Medical and Surgical Sciences, DIMEC, University of Bologna, Bologna; 6Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan; 7Institute of Dermatology, Catholic University of the Sacred Heart, Rome; Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome; 8Dermatologic Clinic, University of Turin Medical School, Turin; 9Medical Oncology Unit; 10Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples; 11Department of Dermatology and Venereology, University of Trieste, Ospedale Maggiore, Trieste, Italy. *Contributed equally.
503 -
Comparison between dutasteride and finasteride in hair regrowth and reversal of miniaturization in male and female androgenetic alopecia: a systematic review
10377PDF: 1835SUPPLEMENTARY MATERIAL: 316HTML: 247 -
25 | EARLY AND MAINTAINED TREAT-TO-TARGET RESPONSE WITH IXEKIZUMAB UP TO 5 YEARS IN MODERATE-TO-SEVERE PSORIASIS: A POST-HOC ANALYSIS OF UNCOVER-3 E. Filippi1, A. Armstrong2, J. F. Merola3, M. Megna4, X. Man5, M. Honma6, J-M. Carrascosa7, R. Chughtai7, K. Fotiou8, S. Sabatino8, M. Ngantcha8, A. Pinter9 | 1Eli Lilly Italia S.p.A, Florence, Italy; 2University of California, Los Angeles, CA, USA; 3University of Texas Southwestern Medical Center, Dallas, TX, USA; 4University of Naples Federico II, Naples, Italy; 5Zhejiang University, Hangzhou, China; 6Asahikawa Medical University, Asahikawa, Japan; 7Hospital Germans Trias, Universitat Autònoma de Barcelona, Barcelona, Spain; 8Eli Lilly and Company, Indianapolis, IN, USA; 9University Hospital Frankfurt, Frankfurt, Germany
132PDF: 45 -
Platelet-rich plasma for the treatment of scleroderma-associated ulcers: a single-center experience and literature review
1136PDF: 582SUPPLEMENTARY MATERIAL: 188HTML: 56

